There were 27 subsequent cancers (18 new and 9 recurrence) in the control group with an incidence rate of 2.4 per 100 p-y and only 1 recurrent cancer in patients under biologics, in particular, anti-TNFα, with incident rates for cancer per 100 p-y of 0.4 for VDZ, 1.8 for USK, and 0.7 for anti-TNFα. The gene discussed is TNF; the disease is cancer.